Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society's highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the Awards Ceremony on Tuesday, September 24, at ASTRO's 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.

5 Jun 2013

Extremely low doses of THC protect the brain from long-term cognitive damage

Though marijuana is a well-known recreational drug, extensive scientific research has been conducted on the therapeutic properties of marijuana in the last decade. Medical cannabis is often used by sufferers of chronic ailments, including cancer and post-traumatic stress disorder, to combat pain, insomnia, lack of appetite, and other symptoms.

31 May 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

EGFR gums up cell's miRNA-processing machinery under oxygen starvation conditions

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs before it's dissolved, researchers reported in an early online publication at Nature.

24 May 2013

Study identifies specific genetic factors that influence occurrence and severity of sepsis

A study published in the June issue of Anesthesiology represents an important first step in establishing new therapeutic options targeting specific genetic areas that influence the occurrence and severity of sepsis - a life-threatening, whole-body response to infection.

23 May 2013

Researchers discover novel mechanism of tumor hypoxia

An article published recently in Tumor Microenvironment and Therapy - an open access journal by Versita, defines a novel mechanism of tumor hypoxia induced by the longitudinal gradient of residual oxygen along tumor vessels as they transverse the tumor.

10 May 2013

WHOI deploys new robotic sensor in Gulf of Maine coastal waters to monitor HABs

A new robotic sensor deployed by Woods Hole Oceanographic Institution in Gulf of Maine coastal waters may transform the way red tides or harmful algal blooms are monitored and managed in New England.

8 May 2013

New study of Antarctic clams reveals age matters when it comes to adapting to effects of climate change

A new study of Antarctic clams reveals that age matters when it comes to adapting to the effects of climate change. The research provides new insight and understanding of the likely impact of predicted environmental change on future ocean biodiversity.

22 Apr 2013

Research: Transcription factors regulating oxygen levels in blood play a role in melanoma metastases

Researchers at the University of North Carolina have discovered that transcription factors regulating the levels of oxygen in the blood also play a role in the spread of the skin cancer melanoma.

17 Apr 2013

UCLA researchers classify kidney cancer into several unique subtypes

Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.

17 Apr 2013

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Diffusion Pharmaceuticals LLC today announced completion of enrollment in a Phase II clinical trial of trans sodium crocetinate, its lead compound for the treatment of cancer.

15 Mar 2013

IU researchers awarded $3.2 million grant to develop new treatments for pancreatic cancer

Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.

14 Mar 2013

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

The effectiveness of sunitinib for the treatment of renal cell carcinoma could be enhanced with the addition of a cyclooxygenase-2 inhibitor, study findings show.

20 Feb 2013

Endothelial cells can trigger changes in cancer cells without direct contact

Blood vessels that supply oxygen and nutrients to tumors can also deliver something else - a signal that strengthens nearby cancer cells, making them more resistant to chemotherapy, more likely to spread to other organs and more lethal, scientists at The University of Texas MD Anderson Cancer Center report online in Cancer Cell.

1 Feb 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

GeneDiagnostics, WILEX partner to commercialize serum HER-2/neu ELISA test in China

WILEX AG today announced that its US subsidiary WILEX Inc., Cambridge, MA, has entered into an exclusive distribution agreement with GeneDiagnostics Inc. for the commercialization of the serum HER-2/neu ELISA test in China.

23 Jan 2013

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

The genetic mutation that causes sickle cell anemia also turns red blood cells into potent tumor killers and may offer a new way to treat cancers that are resistant to existing treatments, according to research published January 9, 2013 in the open access journal PLOS ONE by David S. Terman of Jenomic Research Institute and colleagues from Duke University and other institutions.

10 Jan 2013

Laryngopharyngeal surgery option for outpatients

Laryngopharyngeal surgeries that are performed in an ambulatory setting demonstrate low complication and admission rates, suggesting that such procedures can be carried out safely on an outpatient basis, show findings from a US study.

8 Jan 2013

Heart attack patients may benefit from mild to moderate sleep-disordered breathing

People who suffer from breathing disorders such as sleep apnea are usually at higher risk for cardiovascular disease. But an intriguing new study from Technion-Israel Institute of Technology scientists suggests that some heart attack patients with these conditions may actually benefit from mild to moderate sleep-disordered breathing.

3 Jan 2013

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012